These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 34370275

  • 21. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 22. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Feb; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 23. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
    Piasecka-Stryczyńska K, Kaczyński Ł, Rolka M, Homa M, Staśkiewicz W, Paczwa P, Wójcik R, Kaczor MP, Rejdak K.
    Neurol Neurochir Pol; 2022 Feb; 56(6):480-489. PubMed ID: 36421066
    [Abstract] [Full Text] [Related]

  • 24. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
    Brownlee WJ, Haghikia A, Hayward B, Waser N, Kayaniyil S, Khan Z, Duncan J, Millar S, Harty GT.
    Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465
    [Abstract] [Full Text] [Related]

  • 25. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED.
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [Abstract] [Full Text] [Related]

  • 26. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
    Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV.
    Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
    [Abstract] [Full Text] [Related]

  • 27. The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
    Vermersch P, Galazka A, Dangond F, Damian D, Wong SL, Jack D, Harty G.
    Neurodegener Dis Manag; 2022 Dec; 12(6):285-293. PubMed ID: 35920065
    [Abstract] [Full Text] [Related]

  • 28. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study.
    Comi G, Cook S, Rammohan K, Soelberg Sorensen P, Vermersch P, Adeniji AK, Dangond F, Giovannoni G.
    Ther Adv Neurol Disord; 2018 Dec; 11():1756285617753365. PubMed ID: 29399054
    [Abstract] [Full Text] [Related]

  • 29. Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.
    Rammohan K, Giovannoni G, Comi G, Cook S, Rieckmann P, Soelberg Sørensen P, Vermersch P, Hamlett A, Kurukulasuriya N, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Mult Scler Relat Disord; 2012 Jan; 1(1):49-54. PubMed ID: 25876451
    [Abstract] [Full Text] [Related]

  • 30. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 31. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr 04; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 32. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.
    Mult Scler Relat Disord; 2019 Apr 04; 29():168-174. PubMed ID: 30885375
    [Abstract] [Full Text] [Related]

  • 33. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
    Song Y, Wang Y, Wong SL, Yang D, Sundar M, Tundia N.
    Mult Scler Relat Disord; 2023 Nov 04; 79():105052. PubMed ID: 37832254
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B.
    Mult Scler Relat Disord; 2022 Jan 04; 57():103385. PubMed ID: 35158476
    [Abstract] [Full Text] [Related]

  • 36. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, Giovannoni G, Sormani MP.
    Mult Scler; 2018 Feb 04; 24(2):222-226. PubMed ID: 28140753
    [Abstract] [Full Text] [Related]

  • 37. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
    Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, Damian D, Syed S, Galazka A.
    Mult Scler Relat Disord; 2020 Nov 04; 46():102572. PubMed ID: 33296971
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
    Lizak N, Hodgkinson S, Butler E, Lechner-Scott J, Slee M, McCombe PA, Shaw C, Skibina O, Vucic S, Shuey N, Barnett MH, Parratt J, Butzkueven H, Jack D, Fabris J, Kalincik T.
    Mult Scler; 2021 Mar 04; 27(3):465-474. PubMed ID: 32530363
    [Abstract] [Full Text] [Related]

  • 40. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group.
    Mult Scler; 2011 May 04; 17(5):578-93. PubMed ID: 21228029
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.